Terumo Corp

Terumo Corp. partners with Santersus AG to launch a high‑yield apheresis device that could cut ICU stays and lower sepsis mortality while meeting global reimbursement and cost‑effectiveness goals.

Terumo’s new precision flow‑control IV tubing offers 0.1 mL/min accuracy, cutting infusion drift by 15% and positioning the company as a hidden leader in ICU infusion tech.

Terumo Corporation’s strategic edge in pediatric vascular access, automated cell therapy, prefilled syringes and insulin delivery devices is reshaping the future of healthcare innovation and global supply chains.

Terumo Corporation has made a strategic acquisition of OrganOx, a medtech company, in a bid to expand its presence in the medical technology sector and capitalize on the growing demand for drug-eluting stents.

Terumo Corporation has acquired OrganOx, a UK-based medtech company, for $1.5 billion in a deal expected to strengthen its position in the medical technology sector, particularly in organ transplantation.

Terumo Corporation has acquired OrganOx, a British medtech firm, in a $1.5 billion deal to strengthen its presence in the medical technology sector.

Terumo Corporation has made a $1.5 billion acquisition of OrganOx, a British firm specializing in organ preservation devices, in a move that is being seen as a strategic bet on the company’s future growth, but also carries significant risks.

Terumo Corporation has made a $1.5 billion acquisition of OrganOx, a move that could secure its foothold in the rapidly growing organ transplantation market, but also raises questions about the company’s financial acumen and risk management.

Terumo Corp’s stable stock price and moderate valuation demonstrate the company’s resilience in the face of market fluctuations, making it a promising player in the evolving healthcare industry.

Terumo Corp’s stable performance may be a double-edged sword, masking underlying vulnerabilities and a potentially overvalued stock.